Inside U.S. Trade reports that USTR has begun an “internal review of the controversial pharmaceutical patent proposal that U.S. trade officials tabled” earlier in the TPP negotiations. However, USTR has also signaled new text will not be ready by the next round of negotiations in Singapore in March. The initial U.S. proposal centered around an “access window,” granting TRIPS plus protection to firms that introduced their products within a certain period of time. It was opposed by all of the other negotiators, and the original text was withdrawn.

January 22, 2013

Source: Infojustice

• USTR's decision to impose new tariff does not fully reflect Viet Nam's reality and efforts
• Trump threatens EU with ‘substantial’ tariffs over fines of US tech giants
• Trump tariff fine print reveal raft of exemptions
• Foreign Minister meets EC Vice President in Manila
• This wave of Trump tariffs is likely here to stay; more are coming